Categories Analysis, Earnings, Retail

Guess? stock plunges as Q4 earnings miss estimates

Guess? Inc (GES) reported mixed results for its fourth quarter 2019. While earnings missed Street’s targets, revenue surpassed the estimates. Guess stock, which declined 2% and ended the day at $22.07, slumped more than 10% in the extended trading hours.

The company recorded adjusted net earnings of $58.2 million, a 12.8% increase compared to $51.6 million for the fourth quarter of fiscal 2018. Adjusted earnings per share increased 12.9% to $0.70, compared to $0.62 for the prior-year quarter. GAAP EPS stood at $0.28 compared to $0.01 in the prior-year quarter.

Guess (GES) Q4 2019 earnings infograph

Analysts expected Guess to report earnings of $0.75 per share on revenue of $831.15 million for the quarter ended February 2, 2019.

During Q4 2019, the company concluded that pending legislation related to the conclusions taken on the fiscal 2018 tax return would likely be enacted and result in the payment of transition tax. Guess recorded a reserve of $25.8 million, or a negative impact of $0.32 per share in for the recently reported quarter.

For the first quarter of 2020, the Los Angeles-based firm expects revenue to increase between 2.5% and 3.5% in US dollars. GAAP Loss is expected to be in the range of 29 cents to 25 cents.

For fiscal year 2020, the company estimates revenue to increase between 4% and 5% in US dollars. GAAP EPS is expected to be $1.09 to $1.21.

Carlos Alberini, the new CEO, believes that there are several areas of the operation that offer opportunities for improvement, which should result in operating margin growth over time.

Shares of Guess have gained 6% since the beginning of this year and 13% in the past three months.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

 

 

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top